Wellington Management Group’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
VCM
VPM
Wellington Management Group's DNLI Position: Q1 2026 in Review
Wellington Management Group reduced its Denali Therapeutics (DNLI) stake by 2.2% in Q1 2026, selling an estimated $23.5K and leaving 53,363 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1667.
Wellington Management Group first reported a position in DNLI in Q4 2017 and has held it in 16 quarters since. The position peaked at $312M in Q3 2024. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- Wellington Management Group held 53,363 shares of Denali Therapeutics worth $1.02M as of Q1 2026.
- Wellington Management Group sold 1,180 Denali Therapeutics shares in Q1 2026, an estimated $23.5K.
- Denali Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1667 holding.
- Wellington Management Group first reported a position in Denali Therapeutics in Q4 2017 and has held it in 16 quarters since.
- Wellington Management Group's Denali Therapeutics position peaked at $312M in Q3 2024.
- 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.